Amgen Senior Associate, Safety Biomarkers in South San Francisco, California

Amgen is a values based organization with a powerful sense of shared purpose toward our mission: to serve patients. At our San Francisco facilities, we provide the capabilities, resources, and rewards of a global enterprise, while maintaining the entrepreneurialism and verve that marked our early days as a biotechnology pioneer. We encourage our team members to have fulfilling and meaningful careers through challenging assignments, career development, and valuable opportunities such as this:

Amgen's Comparative Biology and Safety Sciences (CBSS), is expanding at our San Francisco site to meet the needs of our developing R&D organization.

We are seeking a talented and versatile Senior Associate to join our growing Immunobiology and Clinical Pathology group as a member of the team implementing the safety biomarker plans vital to progression of a wide range of novel drug candidates of diverse modalities. Working closely with colleagues in a highly team-oriented and collaborative environment, the Senior Associate will be a key scientific contributor executing the safety biomarker strategy in nonclinical species, and will actively participate in issue resolution plans aimed at solving complex and challenging scientific questions.


Responsible for the implementation of protocols and experimental plans of approved safety biomarker projects, and accountable for high quality, and impactful data and interpretations.

Apply broad scientific background and technical expertise across a wide variety of available platforms to investigate and solve a wide range of challenging diverse scientific questions.

Investigate novel platforms and technologies that can contribute to the next generation safety biomarkers, and welcome opportunities to adopt new scientific tools and methodologies to deliver results.

Basic Qualifications:

Master's Degree


Bachelor's degree and 2 years of scientific experience

Preferred Qualifications:

Master's degree in molecular or cell biology, immunology, clinical pathology, or a related discipline with 1+ year of experience in the biotechnology and/or pharmaceutical industry with a focus on safety biomarker development and implementation

Knowledge and experience of drug safety assessment in the pharmaceutical industry

Laboratory experience in preclinical biomarker discovery/validation with expertise in high sensitivity protein and/or nucleic acid based platforms (traditional and single molecule arrays, Luminex, Quanterix, Singluex, MSD and others)

Demonstration of scientific excellence, curiosity, proactivity, critical thinking and review

Thrive within change, highly adaptable and embrace new challenges with a positive attitude

Scientifically nimble, multipurposed and adaptable

Inspired by innovation and out-of-the-box thinking

A Fortune 150 company operating in nearly 100 countries around the world, we invest in highly skilled, dedicated and collaborative individuals who are ready to contribute to our mission in meaningful ways and make a difference in the lives of our patients. That's why, as a member of our cross functional, cross discipline team, we provide you with valuable opportunities to broaden your experience and maximize your potential. Focused on the industry's most

compelling scientific discoveries and housed within industry leading facilities within the heart of the world's leading biotechnology hub, our colleagues are growing our pipeline through groundbreaking innovations. We believe in rewarding those who do rewarding work and are committed to providing careers that can help turn the tide of serious, life interrupting illnesses.

Amgen is an Equal Opportunity employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status.

Amgen will consider for employment qualified applicants with criminal histories in a manner consistent with the San Francisco Fair Chance Ordinance.